WO2005121136A1 - Salt of phosphoric acid with 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)-ethoxy] benzy] thiazolidin-2,4-dione and a method of its preparation - Google Patents
Salt of phosphoric acid with 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)-ethoxy] benzy] thiazolidin-2,4-dione and a method of its preparation Download PDFInfo
- Publication number
- WO2005121136A1 WO2005121136A1 PCT/CZ2005/000040 CZ2005000040W WO2005121136A1 WO 2005121136 A1 WO2005121136 A1 WO 2005121136A1 CZ 2005000040 W CZ2005000040 W CZ 2005000040W WO 2005121136 A1 WO2005121136 A1 WO 2005121136A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- salt
- phosphoric acid
- thiazolidin
- dione
- ethoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- the invention concerns a new salt of rosiglitazone, i.e. of 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)-ethoxy]benzyl]thiazolidin-2,4-dione, with phosphoric acid (H 3 PO 4 ), including a method of its preparation and physical and chemical properties.
- the salt can be used to prepare pharmaceuticals for treatment of hyperglycemia in patients with diabetes mellitus of type 2.
- 2,4-dione of formula I is a known anti-hyperglycemic agent, which was first described in patent EP306228 (1989) of Beecham. Rosiglitazone is in praxis used in the form of salts, especially with maleic acid (WO 9405659 Al, formula II). Recently, a number of crystalline modifications of rosiglitazone maleate II and of its hydrates have been known (WO 2000064893 A2 and WO 2000064892 A2, WO 2002026737 Al, WO 9931095 Al, WO 9931094 Al and WO 9931093 Al). A number of other addition salts is also known, both with mineral acids and with strong organic acids (WO 0220519 Al, WO 0220518 Al).
- the solution being described comprises a new salt of rosiglitazone of formula I with phosphoric acid, which surprisingly shows a number of advantageous qualities that have not yet been observed in the above described salts.
- the invention concerns a salt of phosphoric acid with 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]-benzyl]thiazolidin-2,4-dione, described by formula III, and a method of its preparation.
- the method allows preparing a hitherto undisclosed salt of rosiglitazone of formula I with phosphoric acid (H 3 PO 4 ) in high yield and quality required for pharmaceutical substances.
- our product is a salt that contains a component described by formula I and phosphoric acid (H 3 PO ) in the ratio 1:1, i.e. rosiglitazone dihydrogenphosphate.
- the chemical structure of the salt we have obtained can be described by formulae III, Ill-a, III- b and III-c, which are equivalent to each other. However, for the sake of simplicity, formula III will be used further on in the text. It can be assumed that the obtained salt shows anti- hyperglycemic activity as do other salts of rosiglitazone. An economically viable method of preparation of the salt has also been found, which can be used also on the production scale.
- the method of preparation according to the invention consists in a reaction of 5-[4-[2-(N- methyl-N-(2-pyridyl)-amino)ethoxy]benzyl]thiazolidin-2,4-dione of formula I with concentrated phosphoric acid or its solution, which is carried out in an organic solvent.
- the manufacture of the salt of formula III can be preferably carried out at a temperature close to the boiling point of the used solvent, where good solubility of the starting compound of formula I is ensured.
- the reaction itself can take place at a wide range of temperatures, including temperatures higher than the boiling point of the used solvent at atmospheric pressure. In order to ensure successful accomplishment of the reaction, one can chose reaction temperatures from the interval of 0 up to 150 °C.
- the process of preparation of the salt of formula III is described by the equation in Scheme 1. m Scheme 1
- the choice of the solvent depends on solubility of the starting substance and the product.
- Alcohols e.g. methanol, ethanol, 1-propanol, 2-propanol, butanols
- esters of carboxylic acids e.g. ethyl acetate
- ethers e.g. dioxane, tetrahydrofuran, diethyl ether
- ketones e.g. acetone, cyclohexanone
- acetonitrile their arbitrary mixtures and mixtures with water in any ratios can be used as solvents.
- An advantageous form of the salt of formula III is the crystalline form, which is chemically stable, chemically very pure (above 99.5% according to HPLC), well soluble in water and in aqueous solutions of hydrochloric acid, which can be prepared in high yields in the defined crystalline modification, and which is characterized by suitable particle size for further processing.
- the above-described crystalline salt of formula III is well soluble in water and in aqueous solutions of hydrochloric acid. Especially the solubility in solutions of hydrochloric acid is very important considering the acidobasic conditions in the digestive system (especially in the stomach). It offers indication of the solubility of the substance after it is digested, which is a very important factor for evaluating pharmaceutical effectiveness of the substance.
- a comparison of the solubility of the salt of formula III in acidic environment with that of several other rosiglitazone salts is documented in Example 7.
- Fig. 1 is the X-Ray powder diffraction of the crystalline salt of phosphoric acid with rosiglitazone (III) prepared according to Examples 1 and 2.
- Fig. 2 depicts the DSC curve of the crystalline salt of phosphoric acid with rosiglitazone (III) prepared according to Example 1.
- Fig. 3 depicts the DSC curve of an equimolar mixture of the crystalline salt of phosphoric acid with rosiglitazone (III) and the free base of rosiglitazone (I) prepared according to Example 3.
- Fig. 4 is the 13 C CP-MAS NMR spectrum of the crystalline salt of phosphoric acid with rosiglitazone (III) prepared according to Example 1.
- Fig. 5 is the 31 P CP-MAS NMR spectra of the crystalline salt of phosphoric acid with rosiglitazone (III) prepared according to Example 1.
- Fig. 6 is the FT-IR spectra of the crystalline salt of phosphoric acid with rosiglitazone (III) prepared according to Example 1.
- Fig. 7 depicts a diagram of distribution of particle sizes according to the maximum dimension
- EXAMPLE 4 10 g of the free base of rosiglitazone (I) was dissolved in 250 ml of boiling ethanol. To the obtained solution, a solution of 3.6 ml of concentrated phosphoric acid (85% H 3 PO 4 ) in 40 ml of ethanol was added. It was left to cool down f eely under stirring for 2.5 hours. After filtration, washing of the filtration cake with 30 ml of ethanol and drying in a vacuum drier, crystalline salt III was obtained, m.p. 173-175 °C. The yield was 93 %.
- ANALYTICAL DATA (A-G): The following analytical data clearly characterize the crystalline salt of rosiglitazone phosphate of chemical formula III.
- the melting points of crystalline salts of rosiglitazone phosphate III were measured at Kofler's block with the heating rate of the sample of 10 °C (up to 150 °C) and 4 °C (above 150 °C) per minute. The measured values of melting points range from 170 to 178 °C. Typical melting-point values are presented in Examples 1-6.
- the DSC recordings were measured using the instrument Perkin Elmer PYRIS 1. The measurements were performed for samples weighingt 3-5 mg. The samples were heated to temperatures 20-210 °C with the heating rate of 10 °C per minute. The measured DSC curves are presented in Figures 2 and 3. The crystalline salt of rosiglitazone phosphate III shows a maximum at the temperature 174 to 175 °C.
- the NMR spectra of the crystalline salt of rosiglitazone phosphate III for phosphorus isotope 31 P were measured using spectrometer Avance 500 Bruker with the measurement frequency 202.46 MHz using technique CP/MAS with sample rotation of 15 kHz. The obtained spectrum is presented in Figure 5. The location of the peak (chemical shift expressed in ppm relative to the ammonium phosphate signal) is: 2.0.
- the distribution of particle sizes was measured microscopically with automatic evaluation of the measurement.
- a diagram of distribution of particle sizes according to the maximum dimension (MaxFeret) is presented in Figure 7.
- the measurement has shown that the crystalline salt of rosiglitazone phosphate HI shows a distribution of particle sizes from 0 to 100 ⁇ m with the maximum in the interval of 0-10 ⁇ m (frequency of incidence about 68 %). More than 99 % of particles had its maximum dimension smaller than 50 ⁇ m.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA200700003A EA010176B1 (en) | 2004-06-10 | 2005-05-25 | Salt of phosphoric acid with 5-p4-[2-(n-methyl-n-(2-pyridyl)amino)-ethoxy]benzyl]thiazolidin-2.4-dione and a method of its preparation |
EP05741667A EP1756100A1 (en) | 2004-06-10 | 2005-05-25 | Salt of phosphoric acid with 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)-ethoxy] benzy] thiazolidin-2,4-dione and a method of its preparation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CZ20040712A CZ296468B6 (en) | 2004-06-10 | 2004-06-10 | Salt of phosphoric acid with 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and process for its preparation |
CZPV2004-712 | 2004-06-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005121136A1 true WO2005121136A1 (en) | 2005-12-22 |
Family
ID=34981408
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CZ2005/000040 WO2005121136A1 (en) | 2004-06-10 | 2005-05-25 | Salt of phosphoric acid with 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)-ethoxy] benzy] thiazolidin-2,4-dione and a method of its preparation |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1756100A1 (en) |
CZ (1) | CZ296468B6 (en) |
EA (1) | EA010176B1 (en) |
UA (1) | UA87855C2 (en) |
WO (1) | WO2005121136A1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0306228A1 (en) * | 1987-09-04 | 1989-03-08 | Beecham Group Plc | Substituted thiazolidinedione derivatives |
WO1994005659A1 (en) * | 1992-09-05 | 1994-03-17 | Smithkline Beecham Plc | Substituted thiazolidinedione derivatives |
WO2000063205A2 (en) * | 1999-04-20 | 2000-10-26 | Smithkline Beecham P.L.C. | Thiazolidinedione derivative and its use as antidiabetic |
WO2003050113A1 (en) * | 2001-12-13 | 2003-06-19 | Smithkline Beecham Plc | Hydrogensulfate salt of 5-'4-'2-(n-methyl-n-(2-pyridyl)amino)ethoxy!benzyl!thia zolidine-2,4-dione |
WO2005023803A1 (en) * | 2003-09-10 | 2005-03-17 | Biocon Limited | Phosphoric acid salt of 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl] methyl]- 2,4-thiazolidinedione |
GB2410948A (en) * | 2004-02-13 | 2005-08-17 | Sandoz Ag | Novel phosphoric acid salt of rosiglitazone |
-
2004
- 2004-06-10 CZ CZ20040712A patent/CZ296468B6/en not_active IP Right Cessation
-
2005
- 2005-05-25 WO PCT/CZ2005/000040 patent/WO2005121136A1/en active Application Filing
- 2005-05-25 EA EA200700003A patent/EA010176B1/en not_active IP Right Cessation
- 2005-05-25 EP EP05741667A patent/EP1756100A1/en not_active Withdrawn
- 2005-05-25 UA UAA200700258A patent/UA87855C2/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0306228A1 (en) * | 1987-09-04 | 1989-03-08 | Beecham Group Plc | Substituted thiazolidinedione derivatives |
WO1994005659A1 (en) * | 1992-09-05 | 1994-03-17 | Smithkline Beecham Plc | Substituted thiazolidinedione derivatives |
WO2000063205A2 (en) * | 1999-04-20 | 2000-10-26 | Smithkline Beecham P.L.C. | Thiazolidinedione derivative and its use as antidiabetic |
WO2003050113A1 (en) * | 2001-12-13 | 2003-06-19 | Smithkline Beecham Plc | Hydrogensulfate salt of 5-'4-'2-(n-methyl-n-(2-pyridyl)amino)ethoxy!benzyl!thia zolidine-2,4-dione |
WO2005023803A1 (en) * | 2003-09-10 | 2005-03-17 | Biocon Limited | Phosphoric acid salt of 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl] methyl]- 2,4-thiazolidinedione |
GB2410948A (en) * | 2004-02-13 | 2005-08-17 | Sandoz Ag | Novel phosphoric acid salt of rosiglitazone |
Non-Patent Citations (1)
Title |
---|
SORBERA L A ET AL: "ROSIGLITAZONE MALEATE", DRUGS OF THE FUTURE, BARCELONA, ES, vol. 23, no. 9, 1998, pages 977 - 985, XP000856586, ISSN: 0377-8282 * |
Also Published As
Publication number | Publication date |
---|---|
CZ2004712A3 (en) | 2006-01-11 |
EA200700003A1 (en) | 2007-04-27 |
EP1756100A1 (en) | 2007-02-28 |
EA010176B1 (en) | 2008-06-30 |
CZ296468B6 (en) | 2006-03-15 |
UA87855C2 (en) | 2009-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010114943A1 (en) | Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof | |
WO2017008773A1 (en) | Crystalline forms of obeticholic acid | |
EP2782912A1 (en) | Solid state forms of vilazodone and vilazodone hydrochloride | |
JP2021063111A (en) | Solid state forms of palbociclib dimesylate | |
EP3743405B1 (en) | Crystalline siponimod fumaric acid and polymorphs thereof | |
WO2007080362A1 (en) | Pharmaceutically acceptable co-crystalline forms of sildenafil | |
EP1771444B1 (en) | Salt of oxalic acid with 5-[4-[2-(n-methyl-n-(2-pyridyl)-amino)ethoxy]benzyl]thiazolidin-2,4-dione and a method of its preparation and its use | |
US20090012296A1 (en) | Processes for the preparation of crystalline form beta of imatinib mesylate | |
WO2005121136A1 (en) | Salt of phosphoric acid with 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)-ethoxy] benzy] thiazolidin-2,4-dione and a method of its preparation | |
WO2012007453A1 (en) | Crystalline compound of 1-[4-(2-azepan-1-ylethoxy)benzyl]-2-(4-hydroxyphenyl)-3-methyl-1h-indol-5-ol | |
US20110165202A1 (en) | Solid state forms of fosamprenavir calcium salt and processes for preparation thereof | |
EP2016052B1 (en) | Crystalline (3-cyano-1h-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate | |
KR102466729B1 (en) | Hexadecyl treprostinil crystals and methods for preparation thereof | |
CN114805216A (en) | Olapari crystal form and preparation method thereof | |
US7943786B2 (en) | Process for preparing amorphous (4R-cis)-6-[2-[3-phenyl-4-(phenylcarbamoyl)-2-(4-fluorophenyl)-5-(1-methylethyl)-pyrrol-1-yl]-ethyl]-2,2-dimethyl-[1,3]-dioxane-4-yl-acetic acid | |
CN115521205B (en) | Crystal form of diacerein sodium salt and preparation method thereof | |
EP3357909A1 (en) | Crystalline 4-[3-(methylsulfonyl)phenyl]-1-propyl-piperidine | |
CN116041323A (en) | Acid salt of Sigma-1 receptor agonist, crystal form thereof, preparation method and application thereof | |
JP2023537237A (en) | Crystalline salts of tizoxanide and 2-hydroxy-N-(5-chloro-1,3-thiazol-2-yl)benzamide (RM-4848) with ethanolamine, morpholine, propanolamine, piperazine, and N-methylpiperazine | |
WO2022250620A1 (en) | An improved process for highly pure benserazide hydrochloride and novel anhydrous polymorph thereof | |
CN115894356A (en) | Crystal forms of regorafenib sulfate and hydrochloride and preparation method thereof | |
WO2010067136A1 (en) | Novel crystalline forms | |
SK50092006A3 (en) | Aripiprazole salts and a method for preparation thereof | |
WO2016198117A1 (en) | New crystal forms of minodronic acid | |
SI21424A (en) | Procedure of purification of losartan |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005741667 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200700003 Country of ref document: EA |
|
WWP | Wipo information: published in national office |
Ref document number: 2005741667 Country of ref document: EP |